Shopping Cart
- Remove All
Your shopping cart is currently empty
Napyradiomycin B4 is a derivative of Napyradiomycin that inhibits the RANKL-induced MEK-ERK signaling pathway. It reduces osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis.

| Description | Napyradiomycin B4 is a derivative of Napyradiomycin that inhibits the RANKL-induced MEK-ERK signaling pathway. It reduces osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis. |
| In vitro | Napyradiomycin B4 (5 μM, 4 days) inhibits RANKL-induced osteoclast differentiation and promotes the expression of Nrf2-related genes while suppressing the expression of osteoclast-related genes. |
| In vivo | Napyradiomycin B4 (2-12 mg/kg, intraperitoneal injection, 6 days) protects against osteoclast-mediated bone loss in a C57BL/J6 mouse model by inhibiting osteoclast formation, preventing periodontal bone destruction, and demonstrates no significant toxicity. |
| Formula | C25H31Cl3O6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.